(Reuters) – Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan. Teva’s Tel Aviv shares fell to 249.80 shekels ($64) late on Sunday, the first day of trading since both news […]
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that the underwriters for its recently completed underwritten public offering of common stock have partially exercised their option to purchase additional shares of common stock from Epizyme. The underwriters purchased 701,448 shares from Epizyme at […]
Athersys Inc’s stem-cell therapy, its only product to reach human trials, failed a mid-stage study testing it as a treatment for a type of stroke, wiping off more than 40 percent of the company’s market value. Data showed on Friday that patients given the therapy, MultiStem, did not show a significant difference from those given […]
Mylan Executive Chairman Robert J. Coury commented, “We note that there has been some media speculation with regard to a potential bid for Mylan by Teva and that this rumor has been circulating for some time. Although it has been company policy not to comment on such media speculation, given current circumstances, we believe it […]
AbbVie Inc. today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics Inc. to 5 p.m., New York City time, on May 1, 2015. On April 17, 2015, AbbVie also voluntarily withdrew its initial Notification and Report Form under the Hart-Scott-Rodino […]
Explorys, a portfolio company of venture capital firm Heritage Group, has been acquired by IBM in an agreement signed April 13. In May 2012, big data company Explorys received a significant investment from the Heritage Healthcare Innovation Fund, a $167 million strategic venture fund that invests in businesses that reduce healthcare costs, improve outcomes and increase […]
Stealth New York-based startup Ovid Therapeutics said this week that former Teva Pharmaceutical Industries Ltd.(TEVA) head Jeremy Levin will become its new chief executive, and that the company has recently inked its first deal with Danish drugmaker Lundbeck. The Lundbeck plan now gives Ovid gaboxadol, a pill which it says may be effective in trials to test its two main disease targets, Angelman syndrome and […]
ThromboGenics NV (TBGNF), a biopharmaceutical company based in Leuven, Belgium, announced that it is teaming up with VIB, a life sciences institute in Flanders (Belgium), to found Oncurious NV, an oncology company. Oncurious will focus on developing TB-403 for the treatment of pediatric brain tumors. TB-403 is a monoclonal antibody that opposes placental growth factor (PIGF). PIGF is observed in several […]
UnitedHealth Group (UNH) says its revenue this year will increase by $2 billion more than earlier projected for 2015 thanks in part to its expansion on public exchanges under the Affordable Care Act and its push to more value-based care contracts with doctors and hospitals. The outlook, which includes increased earnings projections for this year […]
BERKELEY, Calif.–(BUSINESS WIRE)–Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial […]